• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Not Ready for Innovation Guidance Yet, Acting Commissioner Says

FDA Not Ready for Innovation Guidance Yet, Acting Commissioner Says

April 19, 2021

Decentralized clinical trials are here to stay, but the FDA won’t be ready to move forward with more formal recommendations until the pandemic is over, according to Acting Commissioner Janet Woodcock.

Woodcock said many innovations, such as telehealth, were in the early stages of adoption in the clinical trials industry when the pandemic hit. Since then, “everyone has discovered, ‘Gee, it works a lot better than we were worried about.’ So, I think remote clinical trials is something that would be here to stay,” she told attendees of a presentation last week sponsored by the Alliance for a Stronger FDA.

But Woodcock added that two recommendations from the FDA’s COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) initiative — specifically, to clarify plans for existing guidance and publication timing for forthcoming guidances, and to use the experience of the pandemic as a catalyst to defining a broader, agencywide approach to encouraging sustained innovation in clinical trials — would probably have to wait for now. Other innovations on the cusp of greater use are adaptive trials, master protocols and real-world evidence, she added.

“We’re still in the middle of the pandemic and we have to recover, so we will obviously be incorporating some of those things as we go,” Woodcock said. “But some of them will require more broad public input and discussion before we make them an instantiated practice going forward.”

Read the PREPP report here: https://bit.ly/3dXMR6E.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing